Literature DB >> 25245441

Hepatocellular Carcinoma Regression After Cessation of Immunosuppressive Therapy.

Abhijeet Kumar1, Dung T Le2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25245441      PMCID： PMC4886225          DOI： 10.1200/JCO.2013.51.4067

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  21 in total

1.  Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: A one-year randomized, placebo-controlled study.

Authors:  M Weinblatt; B Combe; A Covucci; R Aranda; J C Becker; E Keystone
Journal:  Arthritis Rheum       Date:  2006-09

2.  Abscopal regression of hepatocellular carcinoma after radiotherapy for bone metastasis.

Authors:  K Ohba; K Omagari; T Nakamura; N Ikuno; S Saeki; I Matsuo; H Kinoshita; J Masuda; H Hazama; I Sakamoto; S Kohno
Journal:  Gut       Date:  1998-10       Impact factor: 23.059

3.  Phase I trial of intramuscularly administered tumor necrosis factor in patients with advanced cancer.

Authors:  A A Jakubowski; E S Casper; J L Gabrilove; M A Templeton; S A Sherwin; H F Oettgen
Journal:  J Clin Oncol       Date:  1989-03       Impact factor: 44.544

4.  Improved survival with ipilimumab in patients with metastatic melanoma.

Authors:  F Stephen Hodi; Steven J O'Day; David F McDermott; Robert W Weber; Jeffrey A Sosman; John B Haanen; Rene Gonzalez; Caroline Robert; Dirk Schadendorf; Jessica C Hassel; Wallace Akerley; Alfons J M van den Eertwegh; Jose Lutzky; Paul Lorigan; Julia M Vaubel; Gerald P Linette; David Hogg; Christian H Ottensmeier; Celeste Lebbé; Christian Peschel; Ian Quirt; Joseph I Clark; Jedd D Wolchok; Jeffrey S Weber; Jason Tian; Michael J Yellin; Geoffrey M Nichol; Axel Hoos; Walter J Urba
Journal:  N Engl J Med       Date:  2010-06-05       Impact factor: 91.245

5.  Etanercept plus standard therapy for Wegener's granulomatosis.

Authors: 
Journal:  N Engl J Med       Date:  2005-01-27       Impact factor: 91.245

Review 6.  Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials.

Authors:  Tim Bongartz; Alex J Sutton; Michael J Sweeting; Iain Buchan; Eric L Matteson; Victor Montori
Journal:  JAMA       Date:  2006-05-17       Impact factor: 56.272

7.  Spontaneous regression of a hepatocellular carcinoma--a case report.

Authors:  M Suzuki; N Okazaki; M Yoshino; T Yoshida
Journal:  Hepatogastroenterology       Date:  1989-06

8.  Antitumor effect of human necrosis factor on human hepatoma cells PLC/PRF/5.

Authors:  Y Motoo; N O Hill; M Mahmoudi; K Osther
Journal:  Jpn J Exp Med       Date:  1986-08

9.  Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas.

Authors:  P Geborek; A Bladström; C Turesson; A Gulfe; I F Petersson; T Saxne; H Olsson; L T H Jacobsson
Journal:  Ann Rheum Dis       Date:  2005-02-04       Impact factor: 19.103

10.  Long-term safety, efficacy and inhibition of radiographic progression with abatacept treatment in patients with rheumatoid arthritis and an inadequate response to methotrexate: 3-year results from the AIM trial.

Authors:  Joel M Kremer; Anthony S Russell; Paul Emery; Carlos Abud-Mendoza; Jacek Szechinski; Rene Westhovens; Tracy Li; Xianhuang Zhou; Jean-Claude Becker; Richard Aranda; Charles Peterfy; Harry K Genant
Journal:  Ann Rheum Dis       Date:  2011-10       Impact factor: 19.103
View more
  11 in total

Review 1.  Current concepts of immune based treatments for patients with HCC: from basic science to novel treatment approaches.

Authors:  Tim F Greten; Xin W Wang; Firouzeh Korangy
Journal:  Gut       Date:  2015-02-09       Impact factor: 23.059

Review 2.  Current status and perspectives of immune-based therapies for hepatocellular carcinoma.

Authors:  Maridi Aerts; Daphné Benteyn; Hans Van Vlierberghe; Kris Thielemans; Hendrik Reynaert
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

3.  Spontaneous regression of hepatocellular carcinoma in a Caucasian male patient: A case report and review of the literature.

Authors:  Daniel P Noij; Petrus W G van Der Linden
Journal:  Mol Clin Oncol       Date:  2016-12-22

4.  Spontaneous Regression of Hepatocellular Carcinoma and Review of Reports in the Published English Literature.

Authors:  Moaz B Y Chohan; Nick Taylor; Carla Coffin; Kelly W Burak; Oliver F Bathe
Journal:  Case Rep Med       Date:  2019-03-31

Review 5.  Novel Immunotherapies for Autoimmune Hepatitis.

Authors:  Shamir Cassim; Marc Bilodeau; Catherine Vincent; Pascal Lapierre
Journal:  Front Pediatr       Date:  2017-01-26       Impact factor: 3.418

Review 6.  Spontaneous regression of hepatocellular carcinoma: A mini-review.

Authors:  Akira Sakamaki; Kenya Kamimura; Satoshi Abe; Atsunori Tsuchiya; Masaaki Takamura; Hirokazu Kawai; Satoshi Yamagiwa; Shuji Terai
Journal:  World J Gastroenterol       Date:  2017-06-07       Impact factor: 5.742

7.  Guidelines and tumor boards are required for solid organ recipients with de novo carcinoma.

Authors:  Benoit Rousseau; Aude Guillemin; Christophe Tournigand
Journal:  Oncotarget       Date:  2019-04-19

8.  Pilot study to determine the safety and feasibility of deceased donor liver natural killer cell infusion to liver transplant recipients with hepatocellular carcinoma.

Authors:  Masahiro Ohira; Ryuichi Hotta; Yuka Tanaka; Toshiharu Matsuura; Akin Tekin; Gennaro Selvaggi; Rodrigo Vianna; Camillo Ricordi; Phillip Ruiz; Seigo Nishida; Andreas G Tzakis; Hideki Ohdan
Journal:  Cancer Immunol Immunother       Date:  2021-07-19       Impact factor: 6.968

Review 9.  Immune Therapy for Liver Cancers.

Authors:  Marc Hilmi; Angélique Vienot; Benoît Rousseau; Cindy Neuzillet
Journal:  Cancers (Basel)       Date:  2019-12-27       Impact factor: 6.639

Review 10.  Angiogenesis and immune checkpoint inhibitors as therapies for hepatocellular carcinoma: current knowledge and future research directions.

Authors:  Marc Hilmi; Cindy Neuzillet; Julien Calderaro; Fouad Lafdil; Jean-Michel Pawlotsky; Benoit Rousseau
Journal:  J Immunother Cancer       Date:  2019-11-29       Impact factor: 13.751
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.